A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Jonathan W. Goldman,Robert N. Raju,Gregory A Gordon,Iman El-Hariry,Florentina Teofilivici,Vojo Vukovic,Robert Bradley,Michael D. Karol,Yu Chen,Wei-wei Guo,Takayo Inoue,Lee S. Rosen

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

2013

Jonathan W. Goldman
Robert N. Raju
Gregory A Gordon
Iman El-Hariry
Florentina Teofilivici
Vojo Vukovic
Robert Bradley
Michael D. Karol
Yu Chen
Wei-wei Guo
Takayo Inoue
Lee S. Rosen

Background This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.

Keywords:

Pathology
Ganetespib
HSP90 Heat-Shock Proteins
Stem cell
Hsp90 inhibitor
Pharmacology
Surgical oncology
Maximum tolerated dose
Medicine
Pharmacokinetics
Vomiting
Tolerability
Pharmacodynamics
Nausea
Adverse effect
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations